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Abstract
A 16-year-old, castrated, male English cocker spaniel dog was presented due to generalized alopecia. Routine clinical
pathology, endocrine and abdominal ultrasonography results were consistent with a diagnosis of pituitary-dependent
hyperadrenocorticism. The adenohypophyseal lesion was clearly visualized on both 3 T and 7 T magnetic resonance
imaging (MRI) of the pituitary gland. Although biochemical and MRI findings were consistent with a
functional pituitary microtumor, a pituitary lesion was not detected using 18F-fluorodeoxyglucose positron
emission tomography (FDG-PET). This report firstly describes the application of high-resolution FDG-PET to a
spontaneous pituitary microtumor in a dog.
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Background
Hyperadrenocorticism is a common endocrine disorder
in dogs, whose primary causes are pituitary and adreno-
cortical tumors [1, 2]. However, as many as 80–85 % of
the patients with hyperadrenocorticism are believed to
have chronic excessive secretion of adrenocorticotropic
hormone (ACTH) from a neoplasm within the pituitary
gland [3].
Classically, pituitary tumors have been divided into
microtumors (less than 10 mm in greatest diameter) and
macrotumors (over 10 mm in greatest diameter) [4].
More than half of dogs with pituitary-dependent hypera-
drenocorticism (PDH) have microtumors [5]. The neu-
roradiologic evaluation of pituitary tumors is currently
based on computed tomography (CT) or magnetic reson-
ance imaging (MRI), with or without contrast medium
enhancement [6]. Pituitary macrotumors are well identified
by CT or MRI [7], but microtumors often cannot be visual-
ized in dogs because of small variation in pituitary gland
size and shape [8].
In human medicine, MRI with high-field strength (1.5
to 3 T) is considered to be the most sensitive imaging
modality for the detection of pituitary microtumors [9].
However, up to 40 % of confirmed PDH cases have
negative results in MRI examinations [10, 11]. To over-
come this low detection rate, positron emission tomog-
raphy (PET) with 18F-fluorodeoxyglucose (FDG) has
been used in the diagnosis of microtumors. Previous
studies demonstrated that FDG-PET has the potential
to provide valuable clinical information in the assess-
ment of pituitary microtumors, especially in difficult
cases of biochemically confirmed PDH when other MRI
studies are negative or questionable [10, 12, 13].
Because of the potential value of FDG-PET for
detecting microtumors and limited PET data in dogs,
this imaging technique was applied in the present case
of a pituitary microtumor. This case report firstly
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demonstrates the high-resolution PET characteristics
of a pituitary microtumor in a dog.
Case presentation
Diagnosis of PDH
A 16-year-old, castrated male English Cocker spaniel dog
was presented with a 4 year history of dermatological prob-
lems such as alopecia and pruritus. Polyuria and polydipsia
were not noted by the client. Physical examination revealed
a distended abdomen, generalized alopecia, and seborrheic
dermatitis. Increased alkaline phosphatase activity (ALP:
660 IU/L, reference range: 29–97 IU/L) was observed on
the serum chemistry panel. The levels of total cholesterol
(221 mg/dL, reference range: 135–270 mg/dL) and triglyc-
erides (76 mg/dL, reference range: 21–116 mg/dL) were
within the reference range. Hepatomegaly and bilateral
enlarged adrenal glands of relatively equal size (left:
6.2 mm, right: 5.9 mm in thickness of the cranial
poles) were identified on abdominal radiographs and
ultrasonography, respectively. Because these findings
suggested hyperadrenocorticism, an ACTH stimula-
tion test and a high-dose dexamethasone suppression
test (HDDST) were performed. The serum samples
were obtained for the ACTH stimulation test before
and 1 h after intravenous administration of 0.25 mg
synthetic ACTH (Synacthen, Novartis Pharma, Basel,
Switzerland); pre-ACTH cortisol concentration was
226.2 nmol/L (reference range: 14–166 nmol/L) and
post-ACTH concentration was 717.3 nmol/L (reference
range: 166–469 nmol/L). Serum cortisol concentration was
suppressed after administration of dexamethasone (0.1 mg/
kg intravenously [IV]; Je-Il Pharm, Daegu, South Korea):
pre-HDDST cortisol concentration was 69.5 nmol/L and
4-h and 8-h post-HDDST cortisol concentrations were
40 nmol/L and <27.6 nmol/L, respectively. Based on
these results, a diagnosis of PDH was made.
FDG-PET and 7 T MRI fusion imaging
To evaluate the pituitary gland region, intracranial im-
aging was performed using a high-resolution research
tomography (HRRT)-PET and 7 T MRI fusion imaging
system, with the owner’s permission. Written client con-
sent was obtained prior to examination, and this proced-
ure was performed with the approval of our institutional
review board committee. The dog was fasted for 12 h,
and then injected with FDG (0.4 mCi/kg IV); the dog was
kept caged for 1 h to minimize movement and ensure a
stable FDG uptake. The FDG-PET scan was conducted for
30 min on the HRRT device (resolution, 2.5 mm full width
at half maximum resolution in three-dimensional [3D]
acquisition mode; ECAT HRRT; Siemens, Knoxville, TN,
USA) under general anesthesia maintained by tiletamine/
zolazepam (8 mg/kg IV; Zoletil; Virbac, Carros, France)
following medetomidine (20 μg/kg intramuscularly [IM];
Domitor; Pfizer, Seoul, South Korea) premedication. Im-
mediately after the PET scan, the shuttle system transported
the dog to 7 T-MRI scanner (Magnetom 7 T; Siemens,
Berlin, Germany), and then pre- and post-contrast T1-
weighted 3D magnetization-prepared rapid gradient echo
images (TR: 3000 ms, TE: 2.98 ms, TI: 1100 ms, flip angle:
10°, matrix: 192 × 256 × 256, field of view [FOV]: 96 ×
128 mm2, slab thickness: 128 mm) and transverse T2-
weighted turbo spin echo images (TR: 3000 ms, TE: 72 ms,
flip angle: 60°, matrix: 384 × 384, FOV: 100 mm, slice thick-
ness: 1.5 mm, interslice gap: 0 mm) of the brain were
obtained. To minimize personnel radiation exposure, the
dog was remotely monitored in the approved holding facil-
ity during the recovery from anesthesia.
On MRI, an arcuate lesion was noted in the right-
ventral part of the pituitary gland. It had hypointensity
on pre-contrast T1-weighted images (WI) (Figs. 1a
and 2a) and hyperintensity on T2-WI (Fig. 2c). This
adenohypophyseal lesion displaced the neurohypophy-
sis in the left-dorsal direction. Pre-contrast T1- and
T2-WI of the neurohypophysis showed hyperintensity
(Figs. 1a and 2a) and isointensity (Fig. 2c), respectively.
Following administration of gadolinium-diethylenetriamine
pentaacetic acid (0.1 mmol/kg IV; Omniscan; Nycomed,
Princeton, NJ, USA), signal intensity was increased uni-
formly in the neurohypophysis, while the adenohypophyseal
lesion had no enhancement (Fig. 2b). The height of the
pituitary gland was 4.16 mm and pituitary height/brain area
(P/B) ratio was 0.3. These MRI findings were consistent
with pituitary microtumor. The FDG uptake of the pituitary
gland was not elevated on HRRT-PET scan (Fig. 1b and c).
The standardized uptake value (SUV) was lower in the
pituitary gland (SUV: 1.23) than in the gray matter
(SUV: 3.95). The anatomical location of the pituitary
gland was more precisely identified by the PET-MRI
fusion images (Fig. 1c).
Follow-up MR scan
The dog was treated with trilostane (3 mg/kg orally [PO],
twice daily [BID]; Vetoryl; Dechra, Shrewsbury, UK), and
then post-ACTH cortisol concentration had been main-
tained between 2 and 5 μg/dL. Six months after initial MRI,
a pituitary lesion was monitored by 3 T MRI scan (Achieva
3.0 T multi TX; Philips Healthcare, Best, NL) with follow-
ing sequences: pre- and post-contrast T1-weighted spin
echo imaging (TR: 500 ms, TE: 12 ms, flip angle: 90°,
matrix: 256 × 256, FOV: 150 mm, slice thickness: 3 mm,
interslice gap: 0 mm) and T2-weighted turbo spin echo
imaging (TR: 4000 ms, TE: 80 ms, flip angle: 90°, matrix:
304 × 294, FOV: 130 mm, slice thickness: 3 mm, interslice
gap: 0 mm). Although the height (4.67 mm) and P/B ratio
(0.31) of the pituitary gland were slightly increased, other
MRI findings were not different from the first MRI scan
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(Fig. 2d–f ). Presently, the dog is managed well without
dermatological or neurological abnormalities.
Conclusions
Typical MRI characteristics of pituitary microtumors in-
clude the displaced neurohypophysis and the adenohy-
pophyseal lesion with hypointensity and hyperintensity
on T1- and T2-WI, respectively [5, 8, 14]. Although the
normal pituitary gland has a rapid contrast enhancement
due to the lack of a blood–brain barrier, signal intensity of
a pituitary tumor is usually low after the injection of the
contrast media [14, 15]. In the present case, these features
of a pituitary microtumor were noted on MRI scans, which
were performed twice with a 6 month interval. Pituitary
enlargement was not identified on either of the two MRI
scans, using previously reported reference intervals for
height and P/B ratio (height: 3–7.5 mm; P/B ratio: ≤0.31)
[16, 17]. Canine pituitary tumors are classified as aden-
omas, invasive adenomas, and adenocarcinomas [7, 18]. A
previous MRI study demonstrated that tumor size is the
only variable that determines the type of pituitary tumors
in dogs [7]. In that study, adenomas were the smallest
tumors; lack of contrast enhancement was observed in 10 %
of adenomas. In another study, 1 year follow-up MRI of the
Fig. 1 FDG-PET and 7 T MRI characteristics of a canine pituitary microtumor. Transverse (1), dorsal (2), and sagittal (3) images at the level of the
pituitary gland are pictured from left to right. a On pre-contrast T1-WI, the hyperintense neurohypophysis (arrow) was displaced in the left-dorsal
direction by the arcuate adenohypophysis with hypointensity (arrowheads). b On PET images, high FDG uptake is represented by reddish to
yellowish color, while low uptake is represented by bluish to greenish color. Glucose metabolism of the pituitary gland (arrowheads) was relatively
lower than that of the cerebral cortex and the white matter. c The anatomical location of the pituitary gland (arrowheads) was clearly identified
by combining 7 T MRI images with PET images
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pituitary gland showed no apparent change of tumor size in
half of dogs with a visible tumor on the initial MRI scan
[19]. Even though the present case had the imaging features
of adenomas, the characterization of tumor type was impos-
sible because of no histologic data.
High-field MRI is the imaging technique of choice in
humans with pituitary tumors because of its superior
contrast resolution. In human patients with PDH, the
sensitivity of 3 T MRI in detecting pituitary microtu-
mors is relatively higher than that of 1.5 T MRI [20]. In
addition, 3 T and 7 T MRI provide good spatial and
contrast resolution for the identification of clinically
relevant brain anatomy in dogs [21, 22]. In the present
case, the two high-field MRI scanners clearly showed a
pituitary lesion because the image quality for T1- and
T2-WI was comparable at 3 T and 7 T. Further investi-
gation in a large number of dogs is needed to evaluate
the usefulness of 3 T and 7 T-MRI owing to the lack of
high-field MR data in the diagnosis of pituitary tumors.
Although CT and MRI have been commonly used in
the diagnosis of PDH, detection of pituitary lesions still
remains a problem. Pituitary tumors are detectable by
CT or MRI in less than half of humans and dogs with
PDH [8, 10, 11, 15, 23]. Previously, increased FDG
uptake values were noted in human cases of pituitary
microtumors with no abnormal CT or MRI findings
[10, 12, 13]. The ability of FDG-PET to detect pituitary
macrotumors has been well recognized in human medi-
cine, whereas the FDG-PET appearance of microtumors
is controversial because of frequently observed negative
findings [10, 13, 24]. In the present case, a pituitary le-
sion was not visualized on FDG-PET, even though MRI
and biochemical characteristics were typical for a func-
tional ACTH-secreting microtumor. Macrotumors are
usually functional, locally invasive, and can grow rap-
idly, while microtumors are typically slow-growing and
noninvasive [7]. A previous study showed that FDG up-
take values are higher in pituitary macrotumors than in
microtumors [13]. Additionally, it was reported that the
FDG uptake values of nonfunctional pituitary tumors
are higher than those of functional pituitary tumors
[13, 25, 26]. Therefore, FDG uptake, shown by PET im-
aging, may be more directly related to tumor growth
rate than hormonal secretion (functionality).
Fig. 2 High-resolution MRI characteristics of a canine pituitary microtumor. Following initial 7 T MRI scan (a–c), a pituitary lesion was re-evaluated
by 3 T MRI 6 months later (d–f). a Pre-contrast T1-WI showed the hypointense adenohypophyseal lesion (arrowhead), indicating a pituitary
microtumor, and the hyperintense neurohypophysis (arrow). b Uniform contrast enhancement was observed on the neurohypophysis
(arrow), while the adenohypophyseal lesion had no enhancement (arrowhead) on post-contrast T1-WI. c T2-WI revealed hyperintensity in
the adenohypophyseal lesion (arrowhead) and isointensity in the neurohypophysis (arrow). At 6 month follow-up, MRI findings of the
adenohypophyseal lesion (arrowhead) and the neurohypophysis (arrow) were not changed on pre- (d) and post- (e) contrast T1-WI and
T2-WI (f), except for a slight increase in the size of the pituitary gland
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The normal pituitary glands do not accumulate FDG and
are not visualized by FDG-PET imaging of the human brain
[27]. Among the intracranial structures of dogs, the pituitary
gland has the second lowest FDG uptake; therefore, similar
to the normal human pituitary gland, the normal canine pi-
tuitary gland cannot be visualized by FDG-PET imaging
[28]. The detection of microtumors by commercial PET/CT
is limited due to its low spatial resolution and partial-
volume effect. To overcome these limitations and improve
the accuracy of FDG uptake measurement in the pituitary
gland, an HRRT-PET and 7 T MRI fusion imaging system
was used for the evaluation of this case. 7 T MRI clearly vi-
sualized the pituitary lesion, whereas FDG uptake was not
detected using PET. Therefore, FDG-PET did not enhance
the diagnostic utility of 7 T MRI in the present case. How-
ever, negative findings could be observed in pituitary micro-
tumors and FDG-PET was applied in only one case of
pituitary microtumor in a dog. Additionally, the routine use
of PET-MRI fusion imaging in PDH cases is difficult pres-
ently, because of no defined consensus on the interpretation
of FDG uptake for the pituitary gland in veterinary medi-
cine. Therefore, further investigation of this imaging tech-
nique is necessary in dogs with PDH, especially in CT or
MRI negative cases.
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